{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:29:14Z","timestamp":1771234154377,"version":"3.50.1"},"reference-count":83,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) stands as an increasingly pressing global health challenge, underscoring the need for timely identification to facilitate effective treatment and prevent the progression of chronic liver disorders. Given the projected scarcity of specialized healthcare professionals, particularly hepatologists and gastroenterologists, the role of pharmacists emerges as pivotal in NAFLD management. This article sheds light on the potential of pharmacists within community pharmacy settings, not as diagnostic entities, but as facilitators in recognizing and screening individuals at elevated NAFLD risk using validated non-invasive tools like portable devices and calculators. By prioritizing patient education, referrals, and continuous monitoring, pharmacists can refine NAFLD management, ultimately advancing patient outcomes. Enhancing pharmacists\u2019 impact in early NAFLD detection and management can be facilitated through collaborations with healthcare institutions and the incorporation of patient self-assessment tools. This collaborative approach holds promise for further promoting improved liver health within the community.<\/jats:p>","DOI":"10.3390\/pharmacy11050151","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T04:53:05Z","timestamp":1695271985000},"page":"151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Expanding Pharmacists\u2019 Role in the Management of Non-Alcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-0274","authenticated-orcid":false,"given":"Majid Mufaqam","family":"Syed-Abdul","sequence":"first","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON M5G 1L7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: A feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: A systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metabolism"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1665-2681(19)30879-8","article-title":"The prevalence of nonalcoholic fatty liver disease in the Americas","volume":"13","author":"Arrese","year":"2014","journal-title":"Ann. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1440-1746.2007.05002.x","article-title":"Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary","volume":"22","author":"Farrell","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1590\/S0102-86502013001100008","article-title":"The spectrum of non alcoholic fatty liver disease in morbidly obese patients: Prevalence and associate risk factors","volume":"28","author":"Feijo","year":"2013","journal-title":"Acta Cir. Bras."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference","volume":"37","author":"Caldwell","year":"2003","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s10620-016-4143-0","article-title":"Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations","volume":"61","author":"Sherif","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/ajg.2017.5","article-title":"Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: An analysis of National Health and Nutrition Examination Survey data","volume":"112","author":"Kabbany","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: From steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1053\/gast.2002.36572","article-title":"AGA technical review on nonalcoholic fatty liver disease","volume":"123","author":"Sanyal","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_21","first-page":"221","article-title":"Molecular pathways in non-alcoholic fatty liver disease","volume":"7","author":"Berlanga","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/edrv.23.2.0461","article-title":"Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes","volume":"23","author":"Lewis","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1139\/h06-092","article-title":"Characteristics of metabolically obese normal-weight (MONW) subjects","volume":"32","author":"Conus","year":"2007","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"ref_30","first-page":"389","article-title":"Lean non-alcoholic fatty liver disease (Lean-NAFLD): A major cause of cryptogenic liver disease","volume":"74","author":"Vos","year":"2011","journal-title":"Acta Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","article-title":"In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not","volume":"62","author":"Younossi","year":"2013","journal-title":"Metabolism"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: A systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1074\/jbc.RA118.001921","article-title":"An unexpected link between fatty acid synthase and cholesterol synthesis in proinflammatory macrophage activation","volume":"293","author":"Carroll","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jgh.12271","article-title":"Characteristics and diagnosis of NAFLD\/NASH","volume":"28","author":"Hashimoto","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms","volume":"10","author":"Wree","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Blencowe, M., Karunanayake, T., Wier, J., Hsu, N., and Yang, X. (2019). Network modeling approaches and applications to unravelling non-alcoholic fatty liver disease. Genes, 10.","DOI":"10.3390\/genes10120966"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.mayocp.2015.06.013","article-title":"Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"90","author":"Spengler","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_41","unstructured":"(2016). Non-Alcoholic Fatty Liver Disease: Assessment and Management National Institute for Health and Care Excellence: Guidance, National Guideline Centre. Ch. Diagnosis of NAFLD."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"key":"ref_43","unstructured":"RCP (2016). Underfunded. Underdoctored. Overstretched, Royal College of Physicians."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5694\/j.1326-5377.2009.tb02320.x","article-title":"On solutions to the shortage of doctors in Australia and New Zealand","volume":"190","author":"Gorman","year":"2009","journal-title":"Med. J. Aust."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2150132721994018","DOI":"10.1177\/2150132721994018","article-title":"Primary Care Shortage in Medically Underserved and Health Provider Shortage Areas: Lessons from Delaware, USA","volume":"12","author":"Malayala","year":"2021","journal-title":"J. Prim. Care Community Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e002236","DOI":"10.1136\/fmch-2023-002236","article-title":"Biopsy of Canada\u2019s family physician shortage","volume":"11","author":"Li","year":"2023","journal-title":"Fam. Med. Community Health"},{"key":"ref_47","first-page":"385","article-title":"Lack of doctors, but for what System? Shortage of clinicians in Italy and Lombardy and reflections on structural constrains in training","volume":"75","author":"Colombo","year":"2019","journal-title":"Ig. Sanit\u00e0 Pubblica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1590\/1413-81232017227.03512017","article-title":"International cooperation and shortage of doctors: An analysis of the interaction between Brazil, Angola and Cuba","volume":"22","author":"Alves","year":"2017","journal-title":"Ci\u00eancia Sa\u00fade Coletiva"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.31425","article-title":"Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage","volume":"72","author":"Russo","year":"2020","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/ajhp\/59.suppl_9.S18","article-title":"Role of the pharmacist in diabetes management","volume":"59","author":"Campbell","year":"2002","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sheng, G., Xie, Q., Wang, R., Hu, C., Zhong, M., and Zou, Y. (2021). Waist-to-height ratio and non-alcoholic fatty liver disease in adults. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01824-3"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1515\/jcim-2020-0073","article-title":"Body composition, phenotype and central obesity indices in Egyptian women with non-alcoholic fatty liver disease","volume":"18","author":"Zaki","year":"2020","journal-title":"J. Complement. Integr. Med."},{"key":"ref_54","first-page":"687","article-title":"Comparative analysis of BIA, IBC and DXA for determining body fat in American Football players","volume":"61","author":"Soni","year":"2021","journal-title":"J. Sports Med. Phys. Fit."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ajcn\/81.1.74","article-title":"Comparison of multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for assessment of percentage body fat in a large, healthy population","volume":"81","author":"Sun","year":"2005","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1381\/0960892055002347","article-title":"Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass","volume":"15","author":"Boza","year":"2005","journal-title":"Obes. Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.soard.2011.06.010","article-title":"Serologic predictors of nonalcoholic steatohepatitis in a population undergoing bariatric surgery","volume":"8","author":"Chisholm","year":"2012","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2001.25540","article-title":"Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese","volume":"121","author":"Dixon","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1590\/0103-0582201432215813","article-title":"Biochemical, anthropometric and body composition indicators as predictors of hepatic steatosis in obese adolescents","volume":"32","author":"Gobato","year":"2014","journal-title":"Rev. Paul. Pediatr."},{"key":"ref_62","first-page":"237","article-title":"Prevalence of Non-Alcoholic Fatty Liver Disease and Its Biochemical Predictors in Patients with Type-2 Diabetes Mellitus","volume":"27","author":"Kabir","year":"2018","journal-title":"Mymensingh Med. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.3346\/jkms.2018.33.e122","article-title":"Biochemical Predictors of Early Onset Non-Alcoholic Fatty Liver Disease in Young Children with Obesity","volume":"33","author":"Kim","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2008.11.021","article-title":"Association of serum uric acid level with non-alcoholic fatty liver disease: A cross-sectional study","volume":"50","author":"Li","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3748\/wjg.15.2132","article-title":"Hyperferritinemia is a risk factor for steatosis in chronic liver disease","volume":"15","author":"Licata","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1590-8658(02)80194-3","article-title":"Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study","volume":"34","author":"Lonardo","year":"2002","journal-title":"Dig Liver Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2036.2011.04788.x","article-title":"Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease","volume":"34","author":"Petta","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/s11695-015-1655-1","article-title":"Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery","volume":"25","author":"Praveenraj","year":"2015","journal-title":"Obes. Surg."},{"key":"ref_69","first-page":"33","article-title":"Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity","volume":"34","author":"Puljiz","year":"2010","journal-title":"Coll. Antropol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.metabol.2010.08.005","article-title":"Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men","volume":"60","author":"Ryu","year":"2011","journal-title":"Metabolism"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11695-010-0118-y","article-title":"A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients","volume":"20","author":"Ulitsky","year":"2010","journal-title":"Obes. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.metabol.2012.08.013","article-title":"Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey","volume":"62","author":"Sirota","year":"2013","journal-title":"Metabolism"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ali, A.H., Al Juboori, A., Petroski, G.F., Diaz-Arias, A.A., Syed-Abdul, M.M., Wheeler, A.A., Ganga, R.R., Pitt, J.B., Spencer, N.M., and Hammoud, G.M. (2022). The Utility and Diagnostic Accuracy of Transient Elastography in Adults with Morbid Obesity: A Prospective Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051201"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.cgh.2020.01.020","article-title":"Dallas steatosis index identifies patients with nonalcoholic fatty liver disease","volume":"18","author":"McHenry","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Mallet","year":"2007","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cgh.2016.03.034","article-title":"Development and validation of the Framingham steatosis index to identify persons with hepatic steatosis","volume":"14","author":"Long","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Syed-Abdul, M.M., Kabir, S.S., Soni, D.S., Faber, T.J., Barnes, J.T., and Timlin, M.T. (2021). Role of Nutrition Education in Pharmacy Curriculum-Students\u2019 Perspectives and Attitudes. Pharmacy, 9.","DOI":"10.3390\/pharmacy9010026"}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/11\/5\/151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:54:44Z","timestamp":1760129684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/11\/5\/151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":83,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["pharmacy11050151"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy11050151","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}